Cubist Systematic Strategies LLC Purchases New Position in Ibere Pharmaceuticals (NYSE:IBER)

Cubist Systematic Strategies LLC acquired a new stake in shares of Ibere Pharmaceuticals (NYSE:IBERGet Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 70,470 shares of the company’s stock, valued at approximately $698,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new position in shares of Ibere Pharmaceuticals during the 3rd quarter valued at $250,000. Mizuho Securities USA LLC bought a new position in Ibere Pharmaceuticals during the third quarter valued at about $398,000. Saba Capital Management L.P. acquired a new stake in shares of Ibere Pharmaceuticals in the first quarter worth about $785,000. Finally, Bank of America Corp DE bought a new stake in shares of Ibere Pharmaceuticals during the 1st quarter worth about $3,139,000. 69.66% of the stock is currently owned by institutional investors and hedge funds.

Ibere Pharmaceuticals Price Performance

Shares of NYSE IBER opened at $10.18 on Friday. The business’s 50-day simple moving average is $10.16 and its 200-day simple moving average is $10.03. Ibere Pharmaceuticals has a 52 week low of $9.74 and a 52 week high of $10.75.

About Ibere Pharmaceuticals

(Get Rating)

Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.

Featured Stories

Want to see what other hedge funds are holding IBER? Visit to get the latest 13F filings and insider trades for Ibere Pharmaceuticals (NYSE:IBERGet Rating).

Institutional Ownership by Quarter for Ibere Pharmaceuticals (NYSE:IBER)

Receive News & Ratings for Ibere Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ibere Pharmaceuticals and related companies with's FREE daily email newsletter.